- 专利标题: Non-nucleoside reverse transcriptase inhibitors
-
申请号: US15012445申请日: 2016-02-01
-
公开(公告)号: US09718819B2公开(公告)日: 2017-08-01
- 发明人: Kenneth L. Arrington , Christopher Burgey , Robert Gilfillan , Yongxin Han , Mehul Patel , Chun Sing Li , Yunfu Luo , Zhiyu Lei
- 申请人: Merck Sharp & Dohme Corp.
- 申请人地址: US NJ Rahway
- 专利权人: Merck Sharp & Dohme Corp.
- 当前专利权人: Merck Sharp & Dohme Corp.
- 当前专利权人地址: US NJ Rahway
- 代理商 Carol S. Quagliato; Catherine D. Fitch
- 优先权: WOPCT/CN2012/001358 20121008
- 主分类号: A01N43/58
- IPC分类号: A01N43/58 ; A01N43/60 ; A61K31/50 ; A61K31/495 ; C07D471/04 ; A61K31/513 ; A61K45/06 ; C07D403/06 ; C07D405/14 ; C07D401/14 ; C07D239/56 ; C07D403/14 ; C07D239/52 ; C07D239/54
摘要:
Compounds of Formula I: are HIV reverse transcriptase inhibitors, wherein R1, R2, RE, L, M and Z are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
公开/授权文献
- US20160145255A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS 公开/授权日:2016-05-26
信息查询
IPC分类: